Daewoong, Medytox divided on US court’s partial dismissal of BTX theft case
Apr 30, 2018
A US court on Friday has partially accepted and partially denied South Korea’s Daewoong Pharmaceutical’s motion to dismiss the claims brought against them by domestic rival Medytox over the origins of the bacterial strain used to produce botulinum toxin products. The two Korean drugmakers involved in the case responded Monday with contradicting interpretations of the court decision, continuing a long-running dispute over the source of their anti-wrinkle drugs.The Superior Court of California in